NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals Inc., a commercial-stage biopharmaceutical company focused on innovative cancer therapies, announced the granting of inducement awards for new employees as part of its 2023 Inducement Plan. On May 1, 2025, the company granted options to purchase up to 188,100 shares of common stock to seven new employees. These stock options will vest over a four-year period, with 25% of the shares vesting after one year and the remainder vesting monthly over the following 36 months, contingent upon the employees' ongoing service with Syndax.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.